IVIG Therapy in Refractory Autoimmune Dysautonomias

Dr. Jill Schofield discusses the potential benefits of IVIG therapy in patients with autoimmune dysautonomias who have not responded to standard treatments. Her presentation at the 2017 Dysautonomia International Conference highlights the complex relationship between the autonomic and immune systems, noting that dysautonomia can often be the initial manifestation of systemic autoimmune diseases. IVIG is a blood-derived product that has shown broad efficacy across several autoimmune disorders, including autonomic neuropathies. Dr. Schofield’s data suggests that IVIG can be effective in improving symptoms in 88% of selected patients with severe refractory dysautonomia within a few weeks to over a year, although responses can vary. She emphasizes the importance of careful patient selection and monitoring for side effects. The therapy is associated with less immune suppression compared to traditional therapies, though it requires precise dosing and monitoring to mitigate risks such as aseptic meningitis and thrombosis.